Australia Markets closed
  • ALL ORDS

    7,728.30
    +15.10 (+0.20%)
     
  • AUD/USD

    0.7277
    -0.0004 (-0.0488%)
     
  • ASX 200

    7,396.90
    +17.70 (+0.24%)
     
  • GOLD

    1,861.20
    -0.20 (-0.01%)
     
  • BTC-AUD

    80,402.59
    +3,648.35 (+4.75%)
     
  • CMC Crypto 200

    1,402.14
    -65.80 (-4.48%)
     

OptimizeRx to Participate in Fireside Chat at the Credit Suisse 30th Annual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

OptimizeRx’s presentation will begin at 11:20 A.M. (track 2) on November 11, 2021

ROCHESTER, Mich., Oct. 25, 2021 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, announced today that Will Febbo, OptimizeRx’s CEO, will participate in a presentation and fireside chat at the upcoming Credit Suisse 30th Annual Healthcare Conference. The virtual healthcare conference is being held from November 8-11, 2021.

Details for the presentation is as follows:

Presentation Date:

November 11, 2021

Time:

11:00 A.M. EST

Track:

2

The presentation will be webcast live and will be available at: https://investors.optimizerx.com/events-and-presentations/presentations

Institutional investors wishing to schedule a one-on-one meeting, please contact your representative at Credit Suisse.

About OptimizeRx
OptimizeRx is the best-in-class health technology company enabling care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. Connecting over 60% of U.S. healthcare providers and millions of their patients through a proprietary point-of-care network, connectivity is facilitated via its integrated Therapy Initiation and Persistence Platform. This powerful digital healthcare solutions platform is transforming market and patient access with the life sciences market by unlocking:

  • AI-directed, real-time HCP marketing to raise awareness of treatment benefits to give patients a timely start on therapy

  • Streamlined communication and processes around therapy initiation to reduce abandonment through simplified enrollment

  • Personalized, successful adherence programs to help patients stay on their doctor-recommended course of therapy

For more information, follow the company on Twitter, LinkedIn or visit www.optimizerx.com.

Important Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

OptimizeRx Contact
Ed Stelmakh, CFO/COO
estelmakh@optimizerx.com

Media Relations Contact
Maira Alejandra, Media Relations Manager
malejandra@optimizerx.com

Investor Relations Contact
Ashley Robinson
LifeSci Advisors, LLC
arr@lifesciadvisors.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting